Sangamo Therapeutics, Inc. (SGMO) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Vaxart, Inc.

Prelude Therapeutics, Inc.

TScan Therapeutics, Inc.

Century Therapeutics, Inc.

Sonnet BioTherapeutics Holdings, Inc.

Sangamo Therapeutics, Inc.

PepGen Inc.

Greenwich LifeSciences, Inc.

Galectin Therapeutics, Inc.

Theseus Pharmaceuticals, Inc.

XBiotech, Inc.

Why is Sangamo Therapeutics, Inc. ?

Poor long term growth as Operating profit has grown by an annual rate -6.97% of over the last 5 years

The company has declared negative results in Jan 70 after 3 consecutive negative quarters

NET SALES(HY) At USD 18.89 MM has Grown at -62.05%
ROCE(HY) Lowest at -480.02%
RAW MATERIAL COST(Y) Grown by 340.42% (YoY)

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -60.80%, its profits have risen by 16.2%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -60.80% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sangamo Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Sangamo Therapeutics, Inc.

-60.41%

-0.39

108.41%

S&P 500

14.9%

0.77

19.29%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-25.91%

EBIT Growth (5y)

-6.97%

EBIT to Interest (avg)

-142.43

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-5.13

Sales to Capital Employed (avg)

3.12

Tax Ratio

0.18%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

43.56%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

21.47

EV to EBIT

-0.94

EV to EBITDA

-1.01

EV to Capital Employed

-4.26

EV to Sales

3.15

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-1748.68%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -76.16 MM

NET PROFIT(HY)

Higher at USD -55.47 MM

DEBT-EQUITY RATIO (HY)

Lowest at -81.76 %

-27What is not working for the Company

NET SALES(HY)

At USD 18.89 MM has Grown at -62.05%

ROCE(HY)

Lowest at -480.02%

RAW MATERIAL COST(Y)

Grown by 340.42% (YoY

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.21 times

OPERATING PROFIT(Q)

Lowest at USD -34.21 MM

PRE-TAX PROFIT(Q)

Lowest at USD -35.64 MM

NET PROFIT(Q)

Lowest at USD -35.48 MM

Here's what is working for Sangamo Therapeutics, Inc.

Operating Cash Flow

Highest at USD -76.16 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Debt-Equity Ratio

Lowest at -81.76 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Sangamo Therapeutics, Inc.

Net Sales

At USD 18.89 MM has Grown at -62.05%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -35.64 MM has Fallen at -118.03%

over average net sales of the previous four periods of USD -16.35 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -35.48 MM has Fallen at -113.53%

over average net sales of the previous four periods of USD -16.62 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Profit

Lowest at USD -34.21 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -35.64 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -35.48 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Debtors Turnover Ratio

Lowest at 4.21 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 340.42% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales